Boston Scientific Corporation

Boston Scientific Corporation

40.59
EUR
+0.44
(+1.10%)
2.08EPS
Feb 03Next Earn
Boston Scientific Corporation
BSEBG:BSX
(Bulgarian Stock Exchange)

Recent

price

40.59

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
5.14
5.05
5.15
5.33
5.57
5.57
6.18
6.6
7.11
7.71
7
8.36
8.87
9.8
11.38
13.56
14.32
Revenue per Share
-0.7
0.29
-2.89
-0.09
-0.09
-0.18
0.26
0.08
1.21
3.38
-0.08
0.69
0.45
1.08
1.26
1.96
2.38
Basic EPS, GAAP
0.03
0.46
0.73
0.61
0.74
0.13
0.5
0.71
-0.13
0.88
0.7
0.93
0.64
1.17
1.61
2.3
2.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.04
0.04
0.02
- -
- -
- -
Dividend per Share
7.43
7.83
5.07
4.95
4.86
4.69
4.94
5.11
6.3
9.95
10.82
11.66
12.26
13.16
14.76
16.34
17.68
Book Value per Share
-3.44
-3.37
-3.98
-3.86
-3.8
-4.71
-4.28
-4.24
-4.01
-3
-0.38
-1.04
-0.87
-0.76
-1.36
-0.72
0.02
Tangible Book Value per Share
1,518
1,509
1,407
1,341
1,324
1,341
1,358
1,370
1,381
1,392
1,417
1,422
1,431
1,453
1,472
1,480
1,472
Basic Weighted Avg Shares
7,806
7,622
7,249
7,143
7,380
7,477
8,386
9,048
9,823
10,735
9,913
11,888
12,682
14,240
16,747
20,074
21,069
Sales/Revenue/Turnover
12.68
12.96
12.84
12.38
12.22
13.24
15.73
16.92
16.89
16.21
6.9
15.34
16.04
16.97
17.93
19.78
20.59
Operating Margin (%)
816
717
683
689
725
769
815
844
894
1,011
1,123
1,093
1,136
1,196
1,269
1,368
1,432
Depreciation Expense
-1,065
441
-4,068
-121
-119
-239
347
104
1,671
4,700
-82
1,041
698
1,593
1,854
2,898
3,502
Net Income, GAAP
- -
31.31
- -
- -
- -
- -
- -
88.75
- -
- -
- -
3.35
38.83
19.8
19.11
14.56
4.43
Effective Tax Rate (%)
-13.64
5.79
-56.12
-1.69
-1.61
-3.2
4.14
1.15
17.01
43.78
-0.83
8.76
5.5
11.19
11.07
14.44
16.62
Profit Margin (%)
1,006
1,298
1,250
1,187
760
1,041
-348
-1,832
-1,257
-167
3,013
2,043
1,957
1,581
521
3,355
2,182
Working Capital
4,934
4,257
4,252
4,237
3,841
5,674
5,420
3,777
4,777
8,861
9,526
9,190
9,262
8,961
8,968
11,137
10,909
LT Debt
11,296
11,353
6,870
6,539
6,457
6,320
6,733
7,012
8,726
13,877
15,326
16,622
17,573
19,530
22,003
24,472
25,873
Total Equity
- -
3.85
- -
- -
- -
- -
- -
1.18
- -
- -
- -
4.54
3.8
6.7
6.79
8.99
10.24
Return on Invested Capital (%)
- -
3.92
- -
- -
- -
- -
- -
1.05
- -
- -
- -
5.38
3.72
6.47
6.83
9.33
10.53
Return on Capital (%)
-9.03
3.89
-44.65
-1.8
-1.83
-3.74
5.32
1.51
21.24
41.59
-0.79
6.17
3.76
8.52
9.03
12.6
14.29
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
41
1,709
1,044
LT Borrowings
10,864
10,791
10,785
LT Finance Leases
124
124
124
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,486
1,447
1,449
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,684
7,972
8,164
Cash, Cash Equivalents & STI
1,453
539
609
Accounts Receivable, Net
3,027
3,049
3,113
Inventories
3,117
3,235
3,317
Total Current Liabilities
4,571
6,428
5,982
Payables & Accruals
3,655
3,987
4,219
ST Debt
41
1,709
1,044
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.38%
9.84%
11.22%
Free Cash Flow
-43.11%
34.41%
43.93%
Net Income, GAAP
6.95%
-240.31%
56.31%
Sales/Revenue/Turnover
10.66%
15.27%
19.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,856
4,120
4,209
4,561
16,747
2025
4,663
5,061
5,065
5,286
20,074
2026
5,203
5,442
5,138
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.22
0.32
0.38
1.26
2025
0.46
0.54
0.51
0.45
1.96
2026
0.9
0.62
0.4
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.

Company News

  • Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?

  • 108,682 Boston Scientific Corporation $BSX Shares Bought by Aberdeen Group plc

  • Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027

  • Bear of the Day: Boston Scientific (BSX)

  • 72,575 Boston Scientific Corporation $BSX Shares Sold by Allspring Global Investments Holdings LLC

  • Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

  • AMG National Trust Bank Acquires 34,303 Shares of Boston Scientific Corporation $BSX

  • Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

  • Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027

  • Insider Buying Signals: 3 Healthcare Stocks to Watch

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

  • Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy?

  • Boston Scientific Corporation $BSX Stock Bought by Ethic Inc.

  • BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX

  • Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

  • BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak

  • Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?

  • Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock

  • SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints